THE SHARE:
Change: -0.01 SEK (-5.12%) / Price: 0.10 SEK / Nov 12, 2025, 12:46 pm (CET)
Home
About
Introduction
Board of Directors
Management Team
Medical Advisors
Corporate Governance
Career
Technology
Physiological Targeting
Functional Nanoparticles
Publications
Patent
Portfolio
Pipeline
SpagoPix
Tumorad
Investor Relations
The Share
Analyst Coverage
Owners
Financial Reports
Financial Calendar
Equity research
Shareholder’s Personal Data
Share Issue
Media
Spago Nanomedical in media
Press Releases
Subscribe
Presentations
Events
Image Bank
Contact
Contact us
mfn-ext-nq-inside-information
14 Oct, 2025
Synligt tumörupptag och rekommenderad doshöjning i Spago Nanomedicals fas I/IIa-studie Tumorad-01
14 Oct, 2025
Visible tumor uptake and recommended dose increase in Spago Nanomedicals’s Phase I/IIa study Tumorad-01
Back